BioSight
Companies
ELI LILLY & Co logo

LLY

NYSEINDIANAPOLIS, IN
ELI LILLY & Co

Eli Lilly discovers, develops, and markets pharmaceutical products across multiple therapeutic areas. The excerpt provided does not contain sufficient detail about their specific therapeutic areas, drug modalities, or pipeline development stages to accurately describe those aspects. Based on the risk factors mentioned, Lilly derives significant revenue from a concentrated set of products, faces generic and biosimilar competition, and operates under pricing agreements with the U.S. government.

$934.60+4.72%1Y
LLY · daily close · illustrative · 0 catalysts marked
$574$720$865$1011$1157Apr '25Aug '25Dec '25Apr '26
1Y high$1108.101Y low$622.37range$485.73(78%)past catalysts

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar